Lysosome Targeted Nanoparticle Aggregation Reverses Immunosuppressive Tumor Microenvironment for Cancer Immunotherapy

被引:2
|
作者
Xing, Yumeng [1 ,2 ,3 ]
Yang, Jianhui [1 ,2 ]
Peng, Ao [1 ,2 ]
Qian, Yujing [1 ,2 ]
Liu, Yang [4 ]
Pan, Pei [2 ]
Liu, Qi [1 ,2 ]
机构
[1] Anhui Med Univ, Affiliated Hosp 2, Res Ctr Translat Med, Hefei 230032, Peoples R China
[2] Anhui Med Univ, Sch Pharm, Hefei 230032, Peoples R China
[3] Xiamen Univ, Coll Chem & Chem Engn, Xiamen 361005, Peoples R China
[4] Nankai Univ, Coll Chem, Tianjin 300071, Peoples R China
基金
中国国家自然科学基金;
关键词
cancer immunotherapy; immunogenic cell death; lysosomal membrane permeabilization; nanoparticle aggregation; PD-1/PD-L1; blockade; MEMBRANE PERMEABILIZATION; CELL-DEATH;
D O I
10.1002/adma.202412730
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Nanotechnology has proven its enormous application value in clinical practice. However, current research on nanomedicines mainly focuses on developing nanoparticles as delivery carriers to maximize the bioavailability of therapeutic agents, with little attention on exploring their potential to directly regulate physiological processes. In this study, inspired by the lysosomal swelling caused by excessive accumulation of undegraded substances, this work presents a lysosomal-targeting aggregated nanoparticle (LTANP) for cancer treatment. By rationally engineering surface composition, properties, and interparticle interactions, LTANP achieves efficient tumor accumulation and selective targeted aggregation in lysosomes of cancer cells, leading to unrelievable lysosomal swelling, and ultimately inducing lysosomal membrane permeabilization (LMP) of cancer cells. Further analysis shows that nanoparticle aggregation-mediated LMP can effectively trigger immunogenic cell death (ICD) by impairing autophagy-lysosome pathway, evoking robust antitumor immune responses and reversing tumor immunogenicity from "cold" to "hot" in a melanoma model. Additionally, LTANP can combine with clinically approved programmed death ligand-1 (PD-L1) antibodies to further unleash T cell-mediated antitumor immunity, significantly enhancing antitumor performance, inhibiting tumor recurrence and metastasis. This work demonstrates the potential of rationally engineered nanostructures in directly combating cancer and provides novel insights for the development of advanced nanoparticle-based cancer treatment. Inspired by the lysosomal swelling caused by excessive accumulation of undegraded substances, a lysosomal-targeting aggregated nanoparticle (LTANP) is synthesized for cancer treatment. By rationally engineering surface properties and interparticle interactions, LTANP enables targeted aggregation in lysosomes of cancer cells, leading to unrelievable lysosomal swelling, and ultimately selectively inducing lysosomal membrane permeabilization and immunogenic cell death of cancer cells. image
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy
    Chauhan, Vikash P.
    Chen, Ivy X.
    Tong, Rong
    Ng, Mei Rosa
    Martin, John D.
    Naxerova, Kamila
    Wu, Michelle W.
    Huang, Peigen
    Boucher, Yves
    Kohane, Daniel S.
    Langer, Robert
    Jain, Rakesh K.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (22) : 10674 - 10680
  • [42] Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment
    Zhou, Wenxi
    Zhou, Yu
    Chen, Xinli
    Ning, Tingting
    Chen, Hongyi
    Guo, Qin
    Zhang, Yiwen
    Liu, Peixin
    Zhang, Yujie
    Li, Chao
    Chu, Yongchao
    Sun, Tao
    Jiang, Chen
    BIOMATERIALS, 2021, 268
  • [43] Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy
    Cao, Yi
    Qiao, Bin
    Chen, Qiaoqi
    Xie, Zhuoyan
    Dou, Xiaoyun
    Xu, Lihong
    Ran, Haitao
    Zhang, Liang
    Wang, Zhigang
    ACTA BIOMATERIALIA, 2023, 160 : 239 - 251
  • [44] Reversal of the immunosuppressive tumor microenvironment by nanoparticle-based activation of immune-associated cells
    Fei-long Qi
    Mei-fang Wang
    Bo-zhao Li
    Ze-fang Lu
    Guang-jun Nie
    Su-ping Li
    Acta Pharmacologica Sinica, 2020, 41 : 895 - 901
  • [45] A dual-enzyme-like photosensitive nanozyme for remodeling the tumor immunosuppressive microenvironment to enhance immunotherapy
    Zheng, Jiahao
    Meng, Wangyang
    Cui, Zepeng
    Tian, Jia
    Zhang, Weian
    BIOMATERIALS, 2024, 311
  • [46] Engineered Nanomaterials for Tumor Immune Microenvironment Modulation in Cancer Immunotherapy
    Xing, Hao
    Li, Xiaomin
    CHEMISTRY-A EUROPEAN JOURNAL, 2024, 30 (32)
  • [47] Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy
    Wei, Gaigai
    Zhang, Huiling
    Zhao, Haiping
    Wang, Jing
    Wu, Nana
    Li, Leying
    Wu, Jiaying
    Zhang, Duanwu
    CANCER LETTERS, 2021, 511 : 68 - 76
  • [48] Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications
    Wu, Peijie
    Han, Jun
    Gong, Yanju
    Liu, Chao
    Yu, Han
    Xie, Na
    PHARMACEUTICS, 2022, 14 (10)
  • [49] Reversal of the immunosuppressive tumor microenvironment by nanoparticle-based activation of immune-associated cells
    Qi, Fei-long
    Wang, Mei-fang
    Li, Bo-zhao
    Lu, Ze-fang
    Nie, Guang-jun
    Li, Su-ping
    ACTA PHARMACOLOGICA SINICA, 2020, 41 (07) : 895 - 901
  • [50] Oncolytic Peptide-Nanoplatform Drives Oncoimmune Response and Reverses Adenosine-Induced Immunosuppressive Tumor Microenvironment
    Wu, Ye
    Lin, Jia-Yi
    Zhou, Yu-Dong
    Liu, Hai-Jun
    Lu, Sheng-Xin
    Zhang, Xiao-Kun
    Guan, Ying-Yun
    Nagle, Dale G.
    Zhang, Wei-Dong
    Chen, Hong-Zhuan
    Luan, Xin
    ADVANCED HEALTHCARE MATERIALS, 2024, 13 (26)